Pregabalin Market Research, 2032
The global pregabalin market size was valued at $1.6 billion in 2022, and is projected to reach $2.2 billion by 2032, growing at a CAGR of 3% from 2023 to 2032. According to the World Health Organization (WHO), epilepsy affects over 50 million individuals worldwide, making it one of the most prevalent neurological conditions. It is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. However, in low-income countries, about three-quarters of people with epilepsy do not receive the necessary therapy; in certain economies, this number reaches 90%. Thus, increase in target population i.e, population affected from neuropathic pain, anxiety, fibromyalgia, epilepsy, and key strategies adopted by market players to suffice the needs in developing and underdeveloped countries boost the growth of the pregabalin market.
Key Takeaways of the Pregabalin Market:
On the basis of type, the tablets and capsules segment dominated the pregabalin market size in terms of revenue in 2022 and is anticipated to grow at the fastest CAGR during the forecast period.
On the basis of application, the neuropathic pain segment dominated the market in terms of revenue in 2022 and is also anticipated to grow at the fastest CAGR during the forecast period.
On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market share in terms of revenue in 2022 and online providers segment is anticipated to grow at the fastest CAGR during the forecast period.
On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.‐¯
Pregabalin is a drug that is mostly used to treat fibromyalgia, neuropathic pain, and specific kinds of seizures. It belongs to the class of drugs known as anticonvulsants or antiepileptics. Pregabalin reduces the release of neurotransmitters involved in the transmission of pain signals by binding to calcium channels in the central nervous system. Pregabalin is frequently used off-label for several ailments, including anxiety disorder, in addition to its FDA-approved applications.
Pregabalin was first created by Pfizer and marketed under the Lyrica brand. The U.S. Food and Drug Administration (USFDA) approved pregabalin for the treatment of neuropathic pain linked to diabetic peripheral neuropathy, postherpetic neuralgia (pain after shingles), and as an adjuvant medication for adult partial-onset seizures. Pregabalin is usually administered orally as a liquid or in the form of capsules. The ailment that is being treated, the patient's reaction to the medicine, and additional variables such as age and general health all affect the dosage and length of treatment.
Market Dynamics
The major factor that drives the pregabalin market growth is an increase in the number of cases of epilepsy, neuropathic pain, and anxiety disorder. Rise in prevalence of epilepsy condition is the major factor that drives the market expansion. Epilepsy is a chronic neurological disorder that requires ongoing treatment with antiepileptic drugs (AEDs) to control seizures. For instance, according to data published by the World Health Organization (WHO), in November 2023, epilepsy emerged as the most common neurological disease, and 5 million people are diagnosed with epilepsy each year. Therefore, the surge in prevalence of epilepsy directly results in a higher demand for pregabalin, which drives the growth of the pregabalin market.
Moreover, rise in awareness about epilepsy and its treatment options among the general population and healthcare professionals contribute toward the pregabalin market forecast The surge in awareness about epilepsy results in higher demand for epilepsy drugs, which is contributes toward the growth of the market. For instance, the month of November is celebrated as National Epilepsy Awareness Month (NEAM) in U.S. During this month, various events, campaigns, and activities are organized to spread awareness about epilepsy and educate the people about epilepsy.
Moreover, the pregabalin market trends such as increase in healthcare investment and surge in R and D activities for other applications has significantly expanded in emerging markets. Rapid urbanization and economic growth in countries such as China and India have created substantial opportunities for manufacturers to cater to the needs of these growing markets.
However, challenges such as alternative treatment and side effects pose hindrances, thereby restraining market growth. Furthermore, initiatives to improve pregabalin's safety and effectiveness when combined with other formulations, contribute to the market growth. Conditions such as neuropathic pain, epilepsy, and anxiety disorders have become more common as the world's older population is increasing, thus boosting the adoption of pregabalin, thereby giving pregabalin market opportunity to key players for market expansion.
Segmental Overview
The pregabalin market is segmented into type, application, distribution channel, and region. On the basis of type, the market is bifurcated into tablet and capsules and others. On the basis of application, the market is classified into neuropathic pain, epilepsy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug store and retail pharmacies, and online providers.
On the basis of region, pregabalin market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and Latin America(Brazil, Argentina, Colombia and rest of Latin America), and Middle East and Africa (GCC, South Africa, North Africa, and rest of LAMEA).
By Type
The tablets and capsules segment accounted for the largest pregabalin market share in terms of revenue in 2022 and is predicted to expand at the highest compound annual growth rate (CAGR) due to their widespread availability, easy administration, and extended-release formulations that impact patient preference for particular formulations. Moreover, key strategies adopted such as product launch of various tablets and products has boosted the market growth.
By Application
The neuropathic pain segment accounted for the largest pregabalin market share in terms of revenue in 2022, owing to the widespread availability of drugs and rise in prevalence of conditions such as diabetic neuropathy, postherpetic neuralgia, and nerve compression syndromes being common contributors. This high prevalence results in a large patient population seeking relief from neuropathic pain symptoms and due to its efficacy.
By Distribution Channel
The drug store and retail pharmacies segment accounted for the largest pregabalin market size in 2022, benefiting from their widespread accessibility and consumer convenience. These outlets serve as primary points of purchase for pharmaceutical products, ensuring broad accessibility to consumers. However, the online providers segment is poised to experience the most rapid growth during the forecast period due to its convenience and accessibility. Online platforms offer consumers a convenient avenue to purchase healthcare products, including pregabalin, eliminating the need to visit physical stores. The ease of ordering, wider product selection, and potential for competitive pricing render online sales an appealing option.
By Region
The pregabalin market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America dominated the global pregabalin market in terms of revenue in 2022, driven by its advanced healthcare infrastructure, substantial investments in R and D, and the presence of major industry players offering pregabalin. On the other hand, Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is attributed to a rise in patient population suffering from epilepsy, neuropathic pain, thus, escalating healthcare expenditures, and rapid technological advancements that significantly contribute to market expansion. The rise in incidence of disease conditions in countries such as China, India, and Southeast Asian nations has spurred the demand for pregabalin.
For the pregabalin market, rising awareness and diagnosis of epilepsy in emerging nations provide profitable prospects. Advanced combination drug technologies are becoming more and more necessary as that are both affordable and effective. Furthermore, the expansion of the biopharmaceutical sector in the Asia-Pacific region, coupled with a focus on innovative formulation and development, has accelerated the adoption of pregabalin technologies. Initiatives aimed at enhancing healthcare accessibility and affordability propel market growth across the region.
Moreover, the substantial population within the Asia-Pacific region presents an extensive pool of individuals for clinical trials and research investigations, thereby amplifying the demand for pregabalin solutions in both preclinical and clinical settings. Governmental support for scientific research initiatives, combined with collaborations between local and global players, is propelling generic availability in pregabalin technologies, positioning Asia-Pacific as an exceptionally dynamic and promising pregablin market during forecast period.
Asia-Pacific offers profitable opportunities for key players operating in the pregabalin market, thereby registering the fastest growth rate during the forecast period, owing to the developments in healthcare infrastructure, rise in R and D activities, as well as well-established presence of domestic companies in the region. In addition, the rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
Moreover, there is potential for ground-breaking breakthroughs in the ongoing generic development efforts. More creative approaches to the design and development of unique formulations provide new opportunities for market participants and result in the production of products with higher efficacies. The current efforts to develop generic pregabalin products have the potential to boost market expansion in developing and underdeveloped economies owing to their low cost, which provide new business prospects for key industry players operating in the pregabalin industry.
Competition Analysis
Competitive analysis and profiles of the major players in the pregabalin market, such as Viatris Inc., Cipla, Amneal Pharmaceuticals, Rising Pharmaceutical, Teva Pharmaceutical, Lupin, ScieGen Pharmaceuticals Inc., Zydus, Medley Pharmaceuticals Ltd., and Novartis AG are provided in the report. Major players have adopted product launch as key developmental strategies to improve the product portfolio of the pregabalin market.
Recent Development in Pregabalin Industry
In May 2022, Lupin Limited (Lupin) announced that it had received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. The product is expected to be manufactured at Lupin’s facility in Aurangabad, India.
In December 2022, Alembic Pharmaceuticals Limited announced that it had received Prior Approval Supplement (PAS) authorization for its Supplemental Abbreviated New Drug Application (sANDA) for Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg from the United States Food and Drug Administration (USFDA).
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pregabalin market analysis from 2022 to 2032 to identify the prevailing pregabalin market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pregabalin market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pregabalin market trends, key players, market segments, application areas, and market growth strategies.
Pregabalin Market Report Highlights
| Aspects | Details |
 Forecast period | 2022 - 2032 |
 Report Pages | 289 |
 By Type |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Teva Pharmaceutical Industries Ltd, Viatris Inc., Cipla, Novartis AG, Lupin Pharmaceuticals, Amneal Pharmaceuticals LLC, Sciegen Pharmaceuticals Inc., Rising Pharmaceuticals, Markans Pharma Ltd., Zydus Group |
Analyst Review
The pregabalin market has witnessed significant growth, primarily driven by the rise in target population and the growing pharmaceutical industry. The increase in prevalence of neuropathic pain, epilepsy, and anxiety with rise in generic approval of pregabalin products, has driven the demand for pregabalin across the globe. Countries such as China, Japan, and India have experienced a surge in healthcare investments, contributing to the expansion of healthcare industry.
In addition, the growing pharmaceutical industry in the developing regions is expected to significantly contribute to the growth of the market. The growth of the pharmaceutical industry has resulted in increased R&D activities for other applications leading to a greater demand for pregabalin.
Furthermore, North America dominated the pregabalin market in terms of revenue in 2022 owing to advanced healthcare infrastructure, substantial investments in R&D, and the presence of major key players in the region. However, Asia-Pacific is expected to witness significant growth during the forecast period, owing to rise in availability of domestic market key players, surge in healthcare expenditure, and rise in population affected due to neuropathic pain, anxiety, epilepsy, and fibromyalgia.
Surge in the approval of generic pregabalin products and rise in the prevalence of epilepsy, neuropathic pain are the upcoming trends of pregabalin market.
Neuropathic pain is the leading application of pregabalin market.
North America is the largest regional market for pregabalin market
The estimated industry size of pregabalin in 2022 is 1.6 billion
Viatris Inc., Cipla, Amneal Pharmaceuticals, Rising Pharmaceutical, Teva Pharmaceutical, Lupin, ScieGen Pharmaceuticals Inc., Zydus, Medley Pharmaceuticals Ltd., and Novartis AG are the top players.
2022 is the base year of pregabalin market.
2032 is the forecast year of pregabalin market.
Loading Table Of Content...
Loading Research Methodology...
